Kateryna Shmanko
Overview
Explore the profile of Kateryna Shmanko including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
183
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
de Castro T, Welland S, Jochheim L, Leyh C, Shmanko K, Finkelmeier F, et al.
Hepatol Commun
. 2024 Nov;
8(11).
PMID: 39495153
Background: Immunotherapy-based combinations are currently the standard of care in the systemic treatment of patients with HCC. Recent studies have reported unexpectedly long survival with lenvatinib (LEN), supporting its use...
2.
Stortz M, Shmanko K, Kraus D, Gairing S, Boedecker-Lips S, Forster F, et al.
Clin Case Rep
. 2023 Nov;
11(11):e8124.
PMID: 37953891
Key Clinical Message: Thrombotic microangiopathies are a side effect of anti-VEGF therapies, which are often limited to the kidneys but can also occur systemically and be life-threatening. Screening for increasing...
3.
Scheiner B, Roessler D, Phen S, Lim M, Pomej K, Pressiani T, et al.
JHEP Rep
. 2022 Dec;
5(1):100620.
PMID: 36578451
Background & Aims: We investigated the efficacy and safety of immune checkpoint inhibitor (ICI) rechallenge in patients with hepatocellular carcinoma (HCC) who received ICI-based therapies in a previous systemic line....
4.
Welland S, Leyh C, Finkelmeier F, Jefremow A, Shmanko K, Gonzalez-Carmona M, et al.
Liver Cancer
. 2022 Aug;
11(3):219-232.
PMID: 35949288
Background: Lenvatinib is approved as first-line treatment for patients with advanced hepatocellular carcinoma (HCC). The efficacy of lenvatinib in Caucasian real-world patients is insufficiently defined. The purpose of this study...
5.
de Castro T, Jochheim L, Bathon M, Welland S, Scheiner B, Shmanko K, et al.
Ther Adv Med Oncol
. 2022 Mar;
14:17588359221080298.
PMID: 35251317
Objective: Evaluation of the efficacy and safety of atezolizumab/bevacizumab in a real-world HCC cohort, including patients with impaired liver function and prior systemic therapy. Methods: Retrospective analysis of 147 HCC...
6.
Scheiner B, Pomej K, Kirstein M, Hucke F, Finkelmeier F, Waidmann O, et al.
J Hepatol
. 2021 Oct;
76(2):353-363.
PMID: 34648895
Background & Aims: Immunotherapy with atezolizumab plus bevacizumab represents the new standard of care in systemic front-line treatment of hepatocellular carcinoma (HCC). However, biomarkers that predict treatment success and survival...